Salvage Photodynamic Therapy Using Talaporfin Sodium for Local Failure of Esophageal Squamous Cell Carcinoma.
esophageal cancer
photodynamic therapy
salvage treatment
squamous cell carcinoma
talaporfin sodium
Journal
Yonago acta medica
ISSN: 0513-5710
Titre abrégé: Yonago Acta Med
Pays: Japan
ID NLM: 0414002
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
08
12
2020
accepted:
05
02
2021
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
2
3
2021
Statut:
epublish
Résumé
Talaporfin sodium photodynamic therapy (TS-PDT) for local failure after chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma has recently been reported to be highly effective and less invasive, compared to other treatment modalities. TS-PDT was recently introduced at the Tottori University Hospital, Japan. The aim of this study is to clarify the efficacy and safety of PDT in our hospital. This was a single-center observational study. We examined eight cases of TS-PDT performed between January 2016 and December 2019. The main endpoints were local complete remission (L-CR) rate and the adverse events. In addition, age, gender, histology, tumor location, TNM stage, tumor depth, irradiation dose, and overall survival (OS) were examined. The patients included 7 men and a woman, with an average age of 72.1 years (range 63-82 years). The baseline clinical stages before CRT or radiotherapy were stage I in 1, stage II in 3, stage III in 3, and stage IVA in 1 patient. The T stage on endoscopic assessment before TS-PDT was T1 in 6 patients and T2 in 2 patients. Treatment outcomes and adverse events were evaluated. There were no treatment-related deaths, and no significant adverse events occurred intraoperatively or postoperatively. The L-CR rate was 7/8 (87.5%); T1 cases had 100% (6/6) L-CR, while T2 cases had 50% (1/2). The 2-year OS rates were 87%. TS-PDT was observed to be safe and effective in the first eight cases of its application following its introduction in our hospital.
Sections du résumé
BACKGROUND
BACKGROUND
Talaporfin sodium photodynamic therapy (TS-PDT) for local failure after chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma has recently been reported to be highly effective and less invasive, compared to other treatment modalities. TS-PDT was recently introduced at the Tottori University Hospital, Japan. The aim of this study is to clarify the efficacy and safety of PDT in our hospital.
METHODS
METHODS
This was a single-center observational study. We examined eight cases of TS-PDT performed between January 2016 and December 2019. The main endpoints were local complete remission (L-CR) rate and the adverse events. In addition, age, gender, histology, tumor location, TNM stage, tumor depth, irradiation dose, and overall survival (OS) were examined.
RESULTS
RESULTS
The patients included 7 men and a woman, with an average age of 72.1 years (range 63-82 years). The baseline clinical stages before CRT or radiotherapy were stage I in 1, stage II in 3, stage III in 3, and stage IVA in 1 patient. The T stage on endoscopic assessment before TS-PDT was T1 in 6 patients and T2 in 2 patients. Treatment outcomes and adverse events were evaluated. There were no treatment-related deaths, and no significant adverse events occurred intraoperatively or postoperatively. The L-CR rate was 7/8 (87.5%); T1 cases had 100% (6/6) L-CR, while T2 cases had 50% (1/2). The 2-year OS rates were 87%.
CONCLUSION
CONCLUSIONS
TS-PDT was observed to be safe and effective in the first eight cases of its application following its introduction in our hospital.
Identifiants
pubmed: 33642911
doi: 10.33160/yam.2021.02.018
pii: 2021.02.018
pmc: PMC7902169
doi:
Types de publication
Journal Article
Langues
eng
Pagination
120-125Informations de copyright
©2021 Tottori University Medical Press.
Références
N Engl J Med. 1992 Jun 11;326(24):1593-8
pubmed: 1584260
Sci Rep. 2018 Aug 27;8(1):12877
pubmed: 30150679
Radiat Oncol. 2019 Oct 17;14(1):178
pubmed: 31623639
J Surg Oncol. 2009 Nov 1;100(6):442-6
pubmed: 19653262
Gen Thorac Cardiovasc Surg. 2007 Nov;55(11):461-4; discussion 464-5
pubmed: 18049854
Gastrointest Endosc. 2005 Jul;62(1):31-6
pubmed: 15990816
Dig Endosc. 2020 May 20;:
pubmed: 32434267
Int J Cancer. 2012 Sep 1;131(5):1228-34
pubmed: 22024814
J Thorac Cardiovasc Surg. 2002 Jan;123(1):175-83
pubmed: 11782772
Ann Transl Med. 2014 Mar;2(3):29
pubmed: 25333005
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):656-64
pubmed: 15708243
Oncotarget. 2017 Mar 28;8(13):22135-22144
pubmed: 28212527
Esophagus. 2019 Jul;16(3):221-245
pubmed: 31098822
Dis Esophagus. 2014 Jan;27(1):42-9
pubmed: 23442160
Gastrointest Endosc. 2003 Jul;58(1):65-70
pubmed: 12838223
J Thorac Cardiovasc Surg. 2000 Jun;119(6):1126-32
pubmed: 10838528